Latest Headlines

Latest Headlines

Up almost one-third in 2014, Cantel falls on Q1 earnings miss

Cantel Medical is up about 30% this year on investor enthusiasm for its sales growth in endoscopy, as well as a brisk acquisition strategy. But its shares were down about 1% in early trading on Dec. 10 after the company reported first quarter earnings that missed expectations a bit.

Meda drops Recipharm contract; plant may be forced to close

Recipharm, a Swedish contract development manufacturer, said it may be forced to eliminate up to 60 jobs and close one of its plants after Meda, a specialty pharmaceutical group, opted to drop one of its contracts with the company.

Bioelectronics startup begins trial to treat Crohn's after early success in RA

SetPoint Medical is starting a clinical trial to treat Crohn's disease patients with its implantable neuromodulation device. The startup previously reported a positive pilot study of the device to treat rheumatoid arthritis.

In wake of IPO, anti-blindness player Pixium expects to file for CE mark

Pixium Vision, which had its IPO in June, is ready to head to European regulators with a retinal implant.

U.K.'s 'Google tax' threatens Big Pharma, Bayer ups R&D outlay, AstraZeneca allies with CRUK

In this week's EuroBiotech Report, weeks after being criticized for encouraging profit-shifting, the United Kingdom unveiled plans to discourage multinationals from funneling money out of the country. The law--dubbed the "Google tax"--is targeted at multinational tech giants but could snare Big Pharma, too. And more.

Zimmer makes a divestiture proposal to appease EU regulators in Biomet acquisition

To address the European Commission's concerns about its proposed $13.4 billion acquisition of Biomet, Zimmer Holdings has proposed the divestiture of "one unicompartmental knee brand and one elbow brand" in the European Economic Areas as well as "one total knee brand" in two European countries.

iRhythm wearable cardiac monitor gets CE mark, CardioLogic partners to sell it in U.K.

iRhythm has received a CE mark in Europe for its continuous heart monitoring Zio Service. The technology enables up to 14 days of continuous heart monitoring via a wireless patch; it includes analytical software, as well as report to the physician. In addition, iRhythm has partnered with cardiology distributor CardioLogic to market Zio in the U.K. for the diagnosis of atrial fibrillation and other cardiac arrhythmias.

Xeltis gets $34M to develop biodegradable heart valves and vessels

Swiss med tech Xeltis has raised €27 million ($34 million) in an oversubscribed Series B round. The financing will be used mostly to help get its first product to market, a biodegradable pulmonary valve intended for patients with severe congenital malformations of the heart, an orphan pediatric indication.

Italy clears Novartis vaccine manufacturing in deaths following vaccinations

Italian authorities last week began recalling two lots of Novartis' influenza vaccine Fluad after more than a dozen deaths were reported in people who had taken the vaccine. But on Monday the Italian Pharmaceutical Agency cleared the manufacturing of the vaccines, saying that the initial analyses of the lots came back "negative."

Eisai opens new plants targeting Asia and Europe

Japanese drugmaker Eisai opened two new plants--one targeting products for Asia and the other aimed at Europe--as part of its plans to expand its global manufacturing operations.